Literature DB >> 9390034

Variation of bcl-2 expression in breast ducts and lobules in relation to plasma progesterone levels: overexpression and absence of variation in fibroadenomas.

G Ferrières1, M Cuny, J Simony-Lafontaine, J Jacquemier, C Rouleau, F Guilleux, J Grenier, P Rouanet, H Pujol, P Jeanteur, C Escot.   

Abstract

Some women with benign breast disease eventually develop breast cancer. The mammary gland undergoes tissue remodelling according to hormonal influences, involving a balance between quiescence, proliferation, and mechanisms of cell death. Proliferation and/or apoptotic events could therefore be investigated to help understand the mechanisms of benign lesion formation and identify mastopathies with a poor prognosis. bcl-2 expression was analysed by immunohistochemistry in 75 benign mastopathies. Protein levels were quantitated with an image analyser in various epithelial structures on frozen sections, including adenoses, fibroadenomas, ductal epithelial hyperplasias, cysts, and apparently normal surrounding lobules and ducts. bcl-2 levels were equivalent in apparently normal lobules and ducts, as well as in cysts and ductal hyperplasias. bcl-2 staining was significantly higher in fibroadenomas, known to be of lobular origin [mean = 10.1, quantitative immunochemistry score (QIC) arbitrary units (AU), n = 19], than in normal lobules (mean = 5.1 AU, n = 43, P = 7 x 10(-5). bcl-2 levels in normal lobules and ducts varied according to the menstrual cycle, being higher during the follicular than the luteal phase (P = 1.8 x 10(-2) and P = 1.7 x 10(-2), respectively). This was further supported by a statistical link (P = 5 x 10(-3) between high levels of circulating progesterone and weak bcl-2 staining in lobules and ducts. This progesterone-dependent variation was absent in fibroadenomas. No statistical correlation was found between bcl-2 expression and circulating levels of oestradiol, and follicle-stimulating or luteotrophic hormones. Although these are only preliminary results, they suggest an influence of progesterone on bcl-2 expression which might be lost in fibroadenomas. A hypothesis is proposed concerning the potential involvement of altered regulation of the apoptotic process in the formation of such benign lesions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9390034     DOI: 10.1002/(SICI)1096-9896(199710)183:2<204::AID-PATH921>3.0.CO;2-M

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  5 in total

Review 1.  Apoptosis in the estrous and menstrual cycles.

Authors:  A C Andres; R Strange
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-04       Impact factor: 2.673

2.  ERα and ERβ expression in correlation with Ki-67, Bcl-2 and Bak in primary tumors and lymph node metastases of breast cancer: The effect of pre-operative chemotherapy.

Authors:  Luiza Kanczuga-Koda; Mariusz Koda; Jakub Tomaszewski; Katarzyna Jarzabek; Joanna Lotowska; Marek Baltaziak; Urszula Sulkowska; Maria Sobaniec-Lotowska; Stanisław Sulkowski
Journal:  Oncol Lett       Date:  2010-09-23       Impact factor: 2.967

Review 3.  Benign breast diseases.

Authors:  Carine Courtillot; Geneviève Plu-Bureau; Nadine Binart; Corinne Balleyguier; Brigitte Sigal-Zafrani; Vincent Goffin; Frédérique Kuttenn; Paul A Kelly; Philippe Touraine
Journal:  J Mammary Gland Biol Neoplasia       Date:  2005-10       Impact factor: 2.673

4.  Assessment of the proliferative, apoptotic and cellular renovation indices of the human mammary epithelium during the follicular and luteal phases of the menstrual cycle.

Authors:  Maria Alicia H Navarrete; Carolina M Maier; Roberto Falzoni; Luiz Gerk de Azevedo Quadros; Geraldo R Lima; Edmund C Baracat; Afonso C P Nazário
Journal:  Breast Cancer Res       Date:  2005-02-16       Impact factor: 6.466

5.  Evidence for a stem cell hierarchy in the adult human breast.

Authors:  René Villadsen; Agla J Fridriksdottir; Lone Rønnov-Jessen; Thorarinn Gudjonsson; Fritz Rank; Mark A LaBarge; Mina J Bissell; Ole W Petersen
Journal:  J Cell Biol       Date:  2007-04-09       Impact factor: 10.539

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.